Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD200 activation receptor ligand hP1A8

A humanized peptide ligand of the CD200 activation receptors (CD200ARs), with potential immunostimulating and antineoplastic activities. Upon administration, CD200 activation receptor ligand (CD200AR-L) human P1A8 (hP1A8) targets and binds to CD200ARs complexes on antigen-presenting cells (APCs). This promotes immature dendritic cell (DC) differentiation and cytokine production, and induces a T-cell-mediated immune response against tumor cells. In addition, hP1A8 downregulates the expression of the inhibitory CD200 and PD-1 receptors on APCs and T cells. This inhibits CD200- and PD-1-mediated immunosuppression. CD200, a type 1a transmembrane protein related to the B7 family of co-stimulatory receptors, functions as an immune checkpoint that modulates immune responses through an inhibitory receptor CD200 receptor 1 (CD200R1) and several activation receptors (CD200ARs). It plays an important role in tumor evasion from host immunity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CD200AR-L hP1A8
Code name:hP1A8
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search